SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)

NCT01470469 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

83

Enrollment

INDUSTRY

Sponsor class

Conditions

Generalized Anxiety Disorder (GAD)
Anxiety, Separation
Phobia, Social

Interventions

DRUG: SPD503 (extended-release Guanfacine hydrochloride)
DRUG: Placebo

Sponsor

Shire